Bifidobacterium lactis Bb12 Enhances Intestinal Antibody Response in Formula‐Fed Infants
- 11 January 2012
- journal article
- research article
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 36 (1S), 106S-117S
- https://doi.org/10.1177/0148607111430817
Abstract
Background: Addition of probiotics to infant formula may positively affect immune function in nonexclusively breastfed infants. This study aimed to investigate the effect of infant starter formula containing the probiotic Bifidobacterium animalis subspecies lactis (Bb12) on intestinal immunity and inflammation. Methods: Six-week-old healthy, full-term infants (n = 172) were enrolled in a prospective, randomized, double-blind, controlled clinical trial with 2 groups studied in parallel to a breastfed comparison group. Formula-fed (FF) infants were randomized to partially hydrolyzed whey formula (CON) or the same formula containing 106 colony-forming units (CFU) Bb12/g (PRO) for 6 weeks. Fecal secretory IgA (sIgA), calprotectin, lactate, and stool pH were assessed at baseline, 2 weeks, and 6 weeks. Anti-poliovirus-specific IgA and anti-rotavirus-specific IgA were assessed at 2 and 6 weeks. Results: Among vaginally delivered FF infants, PRO consumption increased (P < .05) fecal sIgA compared to CON. Anti-poliovirus-specific IgA concentration increased (P < .05) in all infants consuming PRO, whereas anti-rotavirus-specific IgA tended to increase (P = .056) with PRO consumption in cesarean-delivered infants. Anthropometrics and tolerance did not differ significantly between FF infants. Conclusions: Infants consuming formula with Bb12 produced feces with detectable presence of Bb12 and augmented sIgA concentration. Furthermore, cesarean-delivered infants consuming Bb12 had heightened immune response, as evidenced by increased anti-rotavirus- and anti-poliovirus-specific IgA following immunization. These results demonstrate that negative immune-related effects of not breastfeeding and cesarean delivery can be mitigated by including Bb12 in infant formula, thereby providing infants a safe, dietary, immune-modulating bacterial introduction.Keywords
This publication has 44 references indexed in Scilit:
- Faecal Calprotectin in Term and Preterm NeonatesJournal of Pediatric Gastroenterology and Nutrition, 2010
- Altered Fecal Microflora and Increased Fecal Calprotectin in Infants with ColicThe Journal of Pediatrics, 2009
- High Faecal Calprotectin Levels in Healthy, Exclusively Breast-Fed InfantsNeonatology, 2009
- Specific probiotics in reducing the risk of acute infections in infancy – a randomised, double-blind, placebo-controlled studyBritish Journal of Nutrition, 2008
- Detection of Bifidobacterium animalis subsp. lactis (Bb12) in the Intestine after Feeding of Sows and Their PigletsApplied and Environmental Microbiology, 2008
- Fecal Calprotectin Concentrations Are Higher in Exclusively Breastfed Infants Compared to Those Who Are Mixed-FedBreastfeeding Medicine, 2008
- Bacterial colonization, probiotics, and clinical diseaseThe Journal of Pediatrics, 2006
- Effects of Bifidobacterium lactis Bb12 Supplementation on Intestinal Microbiota of Preterm Infants: a Double-Blind, Placebo-Controlled, Randomized StudyJournal of Clinical Microbiology, 2006
- High faecal calprotectin concentrations in newborn infantsArchives of Disease in Childhood: Fetal & Neonatal, 2004
- Age-Dependent Variations in Fecal Calprotectin Concentrations in ChildrenJournal of Pediatric Gastroenterology and Nutrition, 2002